SCHEMBL16670365

SCHEMBL16670365

CCN(C(=O)C(Cc1ccccc1)NC(=O)NS(=O)(=O)c1cccc(Br)c1C)c1ccc(OC)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
FPR2 P25090 1/20 0.42
KMT2A Q03164 2/20 0.40
PTPRB P23467 1/20 0.40
BMP1 P13497 2/20 0.39
USP30 Q70CQ3 2/20 0.39
MMP9 P14780 4/20 0.39
MMP2 P08253 3/20 0.39
MMP1 P03956 3/20 0.38
MMP13 P45452 1/20 0.38
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
ALOX15 P16050 1/20 0.37
KEAP1 Q14145 1/20 0.37
MMP3 P08254 2/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16670362 1.00 POLB (0.43) POLBFPR2KMT2APTPRBBMP1
SCHEMBL16670531 0.93 POLB (0.51) POLBFPR2KMT2APTPRBBMP1
SCHEMBL16670530 0.93 POLB (0.51) POLBFPR2KMT2APTPRBBMP1
SCHEMBL16670305 0.89 FPR2 (0.45) POLBFPR2KMT2APTPRBBMP1
SCHEMBL16670307 0.89 FPR2 (0.45) POLBFPR2KMT2APTPRBBMP1
SCHEMBL16681978 0.88 FPR2 (0.40) POLBFPR2KMT2APTPRBBMP1
SCHEMBL18041083 0.86 USP30 (0.45) FPR2KMT2APTPRBBMP1USP30
SCHEMBL16670821 0.86 USP30 (0.45) FPR2KMT2APTPRBBMP1USP30
SCHEMBL16669962 0.86 FPR2 (0.45) FPR2KMT2APTPRBBMP1USP30
SCHEMBL16669963 0.86 FPR2 (0.45) FPR2KMT2APTPRBBMP1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10035760-B2 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2018-07-31 US disclosed
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2016-09-08 US disclosed
EP-3060554-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2016-08-31 EP disclosed
WO-2015061518-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR1E, POLR1G POLB 15/4885FPR2 4162/4885KMT2A 3552/4885
US-10035760-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR1G, POLR1E POLB 14/4885FPR2 4096/4885KMT2A 3630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.